News

Menarini Group Shares NEXPOVIO® (selinexor) Subgroup Data from BOSTON trial at the European Hematology Association Congress, Highlighting Clinical Potential in Relapsed/Refractory Multiple Myeloma

Contenuto disponibile solo in lingua Inglese